Adaptive Biotechnologies (ADPT) EBITDA Margin (2018 - 2026)
Adaptive Biotechnologies (ADPT) posted EBITDA Margin of 14.62% for Q1 2026, down 492.98% sequentially from 2.47% in Q4 2025, and up 296.0% YoY from 3.69% in Q1 2025.
Adaptive Biotechnologies (ADPT) EBITDA Margin (2018 - 2026) Analysis & Trends
Adaptive Biotechnologies (ADPT) has 9 years of EBITDA Margin data on file, last reported at 14.62% in Q1 2026.
- Quarterly EBITDA Margin rose 296.0% year-over-year to 14.62% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1.87% (up 1002.0% YoY) and the FY2025 annual result came in at 5.48%, up 1913.0% from the prior year.
- EBITDA Margin retreated to 14.62% in Q1 2026 per ADPT's latest filing, from 2.47% in the prior quarter.
- The five-year high for EBITDA Margin was 25.23% in Q3 2025, with the low at 322.32% in Q2 2023.
- Average EBITDA Margin over 5 years is 63.15%, with a median of 26.14% recorded in 2024.
- Year-over-year, EBITDA Margin slumped 20207 bps in 2023 and jumped 29619 bps in 2024.
- Adaptive Biotechnologies' EBITDA Margin stood at 70.99% in 2022, then soared by 69 bps to 21.75% in 2023, then soared by 199 bps to 21.61% in 2024, then sank by 111 bps to 2.47% in 2025, then sank by 493 bps to 14.62% in 2026.
- Business Quant data shows ADPT's EBITDA Margin at 14.62% in Q1 2026, 2.47% in Q4 2025, and 25.23% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Waters | 31,055.11 Bn | 31,054.65 Bn | 1.11 Bn | -3.71% |
| 2 | Thermo Fisher Scientific | 191.02 Bn | 187.77 Bn | 7.74 Bn | 16.93% |
| 3 | Danaher | 137.16 Bn | 131.47 Bn | 3.59 Bn | 22.58% |
| 4 | Idexx Laboratories | 42.82 Bn | 42.62 Bn | 722.74 Mn | 31.78% |
| 5 | Natera | 39.09 Bn | 37.99 Bn | 696.04 Mn | -12.21% |
| 6 | Agilent Technologies | 37.61 Bn | 35.81 Bn | 990.00 Mn | 21.74% |
| 7 | Iqvia Holdings | 34.23 Bn | 32.25 Bn | 1.36 Bn | 12.38% |
| 8 | Illumina | 28.14 Bn | 26.98 Bn | 721.00 Mn | 19.16% |
| 9 | Mettler Toledo International | 26.40 Bn | 26.33 Bn | 555.82 Mn | 19.42% |
| 10 | Adaptive Biotechnologies | 3.48 Bn | 3.27 Bn | 52.17 Mn | -14.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.62% |
| Dec 31, 2025 | -2.47% |
| Sep 30, 2025 | 25.23% |
| Jun 30, 2025 | -10.31% |
| Mar 31, 2025 | -17.58% |
| Dec 31, 2024 | 21.61% |
| Sep 30, 2024 | -11.22% |
| Jun 30, 2024 | -26.14% |
| Mar 31, 2024 | -67.30% |
| Dec 31, 2023 | -21.75% |
| Sep 30, 2023 | -78.67% |
| Jun 30, 2023 | -322.32% |
| Mar 31, 2023 | -98.54% |
| Dec 31, 2022 | -70.99% |
| Sep 30, 2022 | -94.98% |
| Jun 30, 2022 | -120.25% |
| Mar 31, 2022 | -163.30% |
| Dec 31, 2021 | -162.39% |
| Sep 30, 2021 | -142.71% |
| Jun 30, 2021 | -129.24% |